热景生物携全矩阵诊断产品精彩亮相，集中展示多款高度适配中亚市场需求的免疫诊断全线产品，全面覆盖各级医院、基层医疗、急诊急救及公共卫生等各类临床应用场景。

化学发光产品线包含 MQ60、C800、C2100 系列机型，满足不同医疗机构高通量、精准化常规检测需求；

• POCT 领域主推 UPT2800 系统，便携易用、快速出结果，完美适配基层医疗机构与急诊现场检测；

• 结核检测核心产品 TB-IGRA，可高效用于结核感染筛查与临床辅助诊断。

未来，热景生物将深化海外本地化运营，赋能中亚医疗发展。

Deepening Presence in Central Asia, Embarking on a New Journey | Hotgen Showcases at KIHE 2026 to Accelerate Global Expansion

From May 20 to 22, 2026, the Kazakhstan International Healthcare Exhibition 2026 (KIHE 2026) officially opened at the Atakent Exhibition Center in Almaty, Kazakhstan.

Hotgen showcased its full portfolio of diagnostic products, highlighting a wide range of immunodiagnostic solutions highly tailored to the needs of the Central Asian market. The product lineup comprehensively covers clinical application scenarios including tertiary hospitals, primary healthcare institutions, emergency care, and public health systems.

The chemiluminescence immunoassay product line featured the MQ60 Series, C800, and C2100, designed to meet the diverse demands of medical institutions for high-throughput and highly accurate routine testing.

In the POCT field, the UPT2800 drew significant attention with its portability, user-friendly operation, and rapid turnaround time, making it an ideal solution for primary healthcare facilities and emergency on-site testing.

Hotgen also presented its core tuberculosis testing product, TB-IGRA, which enables efficient tuberculosis infection screening and clinical auxiliary diagnosis.

Central Asia remains one of Hotgen’s key strategic regions in its global expansion roadmap, with tremendous market potential and growing demand for advanced diagnostic solutions.

Looking ahead, Hotgen will continue to deepen its localized overseas operations and contribute to the advancement of healthcare services across Central Asia.